ATE234838T1 - Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften - Google Patents

Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften

Info

Publication number
ATE234838T1
ATE234838T1 AT96941088T AT96941088T ATE234838T1 AT E234838 T1 ATE234838 T1 AT E234838T1 AT 96941088 T AT96941088 T AT 96941088T AT 96941088 T AT96941088 T AT 96941088T AT E234838 T1 ATE234838 T1 AT E234838T1
Authority
AT
Austria
Prior art keywords
purine derivatives
antipoliferative
rnh
cyclin
effect
Prior art date
Application number
AT96941088T
Other languages
English (en)
Inventor
Laurent Meijer
Emile Bisagni
Michel Legraverend
Miroslav Strnad
Original Assignee
Centre Nat Rech Scient
Inst Botan Experimentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Botan Experimentale filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE234838T1 publication Critical patent/ATE234838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96941088T 1995-12-01 1996-11-29 Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften ATE234838T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514237A FR2741881B1 (fr) 1995-12-01 1995-12-01 Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
PCT/FR1996/001905 WO1997020842A1 (fr) 1995-12-01 1996-11-29 Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques

Publications (1)

Publication Number Publication Date
ATE234838T1 true ATE234838T1 (de) 2003-04-15

Family

ID=9485066

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96941088T ATE234838T1 (de) 1995-12-01 1996-11-29 Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften
AT02293256T ATE500255T1 (de) 1995-12-01 1996-11-29 Purin-derivat zur anwendung in der behandlung einer proliferativen erkrankung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02293256T ATE500255T1 (de) 1995-12-01 1996-11-29 Purin-derivat zur anwendung in der behandlung einer proliferativen erkrankung

Country Status (11)

Country Link
US (6) US6316456B1 (de)
EP (2) EP1308447B1 (de)
JP (1) JP4340796B2 (de)
AT (2) ATE234838T1 (de)
CA (1) CA2238843C (de)
DE (2) DE69626855T2 (de)
DK (2) DK1308447T3 (de)
ES (2) ES2364722T3 (de)
FR (1) FR2741881B1 (de)
PT (2) PT874847E (de)
WO (1) WO1997020842A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066147C (zh) 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EP1003519A4 (de) 1997-03-03 2003-08-20 Univ Texas Unterdrückung von cyclinkinase-2 aktivität zur prävention und therapie dns viraler infektionen
EP1003746A1 (de) 1997-08-07 2000-05-31 The Regents Of The University Of California Purin inhibitoren der protein kinasen, g proteine und polymerasen
CA2301830A1 (en) * 1997-09-05 1999-03-18 Cropdesign N.V. Method and means for modulating plant cell cycle proteins and their use in controlling plant cell growth
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
US7265267B1 (en) 1997-09-16 2007-09-04 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
AU754803B2 (en) * 1997-09-16 2002-11-28 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
CA2307171A1 (en) * 1997-10-24 1999-05-06 Cropdesign N.V. A novel mitogenic cyclin and uses thereof
EP0911634A1 (de) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmazeutische Verwendungen von Regulatoren der CDK-2
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
UA66840C2 (uk) * 1998-02-26 2004-06-15 Авентіс Фармасьютікалз Інк. 6,9-дизаміщені 2-[транс-(4-аміноциклогексил)аміно]пурини, фармацевтична композиція та способи лікування проліферативного розладу, попередження апоптозу нервових клітин, захисту нервових клітин від руйнування
ES2219038T3 (es) * 1998-02-26 2004-11-16 Aventis Pharmaceuticals Inc. 2-(trans-(4-aminociclohexil)amino)purinas 6,9-disustituidas.
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6664439B1 (en) 1998-04-28 2003-12-16 The Procter & Gamble Company Absorbent articles with distribution materials positioned underneath storage material
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
AU1559400A (en) * 1998-12-04 2000-06-26 Cropdesign N.V. Method to identify regulators of cdk activity
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU2004200192B2 (en) * 1999-02-01 2006-11-16 Gilead Palo Alto, Inc. Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
CN1353713A (zh) * 1999-02-01 2002-06-12 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB－α的嘌呤抑制剂
EP1026251A3 (de) * 1999-02-03 2000-09-06 Pfizer Products Inc. Transgene Tiere welche das menschliche p25 Gen exprimieren
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
DE60118521T2 (de) * 2000-01-07 2006-10-12 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
JP2003523358A (ja) * 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 神経変性疾患の治療のためのピリドピリミジノン誘導体
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
ATE301123T1 (de) 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6667311B2 (en) 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
EP1578722A4 (de) * 2001-10-12 2006-09-06 Irm Llc Kinaseinhibitorgerüste und verfahren zu deren herstellung
US20050222054A1 (en) * 2002-03-27 2005-10-06 Cyclacel Limited Combination comprising a CDK inhibitor and doxorubicin
JP2005535631A (ja) * 2002-06-27 2005-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー プリン誘導体の合成
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
AU2003272503A1 (en) * 2002-09-17 2004-04-08 University Of Utah Research Foundation Methods and compositions related to inhibiting nuclear envelope breakdown
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
ATE418333T1 (de) * 2002-11-06 2009-01-15 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
AU2003276463A1 (en) * 2002-11-06 2004-06-07 Cyclacel Limited Combination comprising a cdk inhibitor and cisplatin
WO2004055154A2 (en) * 2002-12-17 2004-07-01 Centre National De La Recherche Scientifique (Cnrs) Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
GB0307640D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
GB0315259D0 (en) * 2003-06-30 2003-08-06 Cyclacel Ltd Use
US20070287718A1 (en) * 2003-11-06 2007-12-13 Green Simon R Methods for the Treatment of Multiple Myeloma Using Roscovitine
EP1765313A2 (de) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen als immunstimulatoren
ES2403558T3 (es) * 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
MX2007004464A (es) 2004-10-13 2007-05-07 Hoffmann La Roche Pirazolobenzodiazepinas disustituidas utiles como inhibidores para cdk2 y angiogenesis, y para el tratamiento de cancer de mama, colon, pulmon y prostata.
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
CA2624025A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5550906B2 (ja) * 2006-10-19 2014-07-16 ゲンズイメ コーポレーション 嚢胞性疾患の治療のためのプリン誘導体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US20100105705A1 (en) * 2007-03-28 2010-04-29 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
MX2009010122A (es) * 2007-03-28 2009-10-19 Neurosearch As Derivados de purinilo y su uso como moduladores del canal de potasio.
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
CZ300774B6 (cs) * 2007-10-05 2009-08-05 Univerzita Palackého Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
PA8809001A1 (es) 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
JP2011207764A (ja) * 2008-07-29 2011-10-20 Univ Of Tokyo Ｃｄｋ阻害剤によるｃ型肝炎ウイルスの複製抑制
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
CZ302623B6 (cs) * 2009-04-22 2011-08-03 Univerzita Palackého Oxalátokomplexy platiny s deriváty N6-benzyladeninu, zpusob jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP2580320B1 (de) 2010-06-14 2018-08-01 The Scripps Research Institute Neuprogrammierung von zellen für ein neues zellschicksal
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP2562265A1 (de) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Empfindlichkeit auf selektive CDK9-Inhibitoren
EP2561867A1 (de) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9-Hemmer zur Behandlung eines Mittellinienkarzinoms
EP2771342B1 (de) 2011-10-28 2016-05-18 Novartis AG Purinderivate und ihre verwendung bei der behandlung von krankheiten
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
JP6286421B2 (ja) * 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン
AU2013263043B2 (en) 2012-05-16 2016-06-16 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
CA2876780A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TN2016000179A1 (en) 2013-12-06 2017-10-06 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
ES2765253T3 (es) 2014-02-17 2020-06-08 Manros Therapeutics Compuestos derivados de purina para uso médico
ES2873959T3 (es) 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10729692B2 (en) * 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
US11994511B2 (en) 2017-04-04 2024-05-28 University Of Miami Biomarkers indicative of prostate cancer and treatment thereof
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN112794853B (zh) * 2021-01-12 2021-11-30 江汉大学 一种有机硒化合物及其制备方法与应用
CN112794852B (zh) * 2021-01-12 2021-11-30 江汉大学 一种含硒有机化合物及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844577A (en) * 1958-07-22 Certificate of correction
US2691654A (en) * 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2830053A (en) * 1955-03-25 1958-04-08 Burroughs Wellcome Co 6-substituted purine compounds and method of making
US2966488A (en) * 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US3213095A (en) * 1963-04-04 1965-10-19 American Cyanamid Co N-benzylation of adenine
US3930005A (en) * 1973-06-15 1975-12-30 Squibb & Sons Inc Antiinflammatory agents and their use
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
DE2355536A1 (de) * 1973-11-07 1975-05-22 Merck Patent Gmbh Adeninderivate und verfahren zu ihrer herstellung
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
DE2550000A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Neue purin-derivate und verfahren zu ihrer herstellung
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4189485A (en) * 1977-08-23 1980-02-19 Takeda Chemical Industries, Ltd. Purine derivatives
DE2804416A1 (de) * 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
EP0363320A3 (de) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
CN1066147C (zh) 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
EP1003746A1 (de) * 1997-08-07 2000-05-31 The Regents Of The University Of California Purin inhibitoren der protein kinasen, g proteine und polymerasen
ATE301123T1 (de) * 2001-06-27 2005-08-15 Cyclacel Ltd 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
JP2005535631A (ja) * 2002-06-27 2005-11-24 エフ．ホフマン−ラ　ロシュ　アーゲー プリン誘導体の合成
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
WO2004035132A2 (en) * 2002-10-15 2004-04-29 Irm Llc Compositions and methods for inducing osteogenesis
US7960397B2 (en) * 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions

Also Published As

Publication number Publication date
DE69626855D1 (de) 2003-04-24
US20100273802A1 (en) 2010-10-28
FR2741881B1 (fr) 1999-07-30
CA2238843A1 (fr) 1997-06-12
DK1308447T3 (da) 2011-06-20
EP1308447B1 (de) 2011-03-02
FR2741881A1 (fr) 1997-06-06
DE69638337D1 (de) 2011-04-14
US20090030019A1 (en) 2009-01-29
ATE500255T1 (de) 2011-03-15
WO1997020842A1 (fr) 1997-06-12
ES2195027T3 (es) 2003-12-01
EP0874847A1 (de) 1998-11-04
DE69626855T2 (de) 2003-12-24
DK0874847T3 (da) 2003-07-14
JP2000501408A (ja) 2000-02-08
PT874847E (pt) 2003-08-29
US20040235868A1 (en) 2004-11-25
EP1308447A1 (de) 2003-05-07
PT1308447E (pt) 2011-06-07
CA2238843C (fr) 2012-04-10
ES2364722T3 (es) 2011-09-13
US8163762B2 (en) 2012-04-24
JP4340796B2 (ja) 2009-10-07
US20020049218A1 (en) 2002-04-25
EP0874847B1 (de) 2003-03-19
US6316456B1 (en) 2001-11-13
US20030186999A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
ATE234838T1 (de) Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften
CO4480021A1 (es) Derivados de amino(tio)eter
DE60040905D1 (de) VERFAHREN ZUR HERSTELLUNG VON (E)-(6-i2-i4-(4-FLUORPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL VINYL (4R,6S)-2,2-DIMETHYLi1,3 DIOXAN-4-YL)ESSIGSÄURE-TERT-BUTYLESTER
ATE415394T1 (de) Zwischeprodukte zur herstellung von retroviralen protease-hemmern
ATE218555T1 (de) Octacylodepsideptide mit endoparasitizider wirkung
DK0657458T3 (da) Inhibitorer af proteinkinase-C
DE69232907T2 (de) Neue heterocyclische/cyclische amine
DE59309819D1 (de) Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten zur Behandlung von Erkrankungen, die durch die nichtenzymatische Glykosylierung bedingt sind
ZA913033B (en) N-(3-fluoro-2-phosphonylmethoxypropyl)derivatives of purine and pyrimidine heterocyclic basis,their preparation and use
ATA152093A (de) Neue guanidin- und amidinsalze von 7-amino-3-hydroxymethyl-3-cephem-4-carbonsäure
DE69830866D1 (de) Verfahren zur Herstellung von Nitroguanidin-Derivaten ausgehend von 2-Nitroimino-hexahydro-1,3,5-triazinen in Anwesenheit von Ammoniak, primärem oder sekundärem Amin
DE59402263D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolid-2-onen
FI930367A (fi) Puridinderivat
DE69425405D1 (de) Verbessertes Verfahren zur Herstellung von 2,4-di(alkylamine)-6-alkylthio-s-Triazinen und 2,4-alkylamine-4,6-di(alkylthio)-s-Triazinen
DE69116251D1 (de) Verfahren zur Herstellung von 6-(substituiertes Aminopropionyl)-Derivaten von Forskolin
DE59008523D1 (de) Verfahren zur Herstellung von Sulfonylharnstoff-Salzen und ihre Verwendung als Herbizide.
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
ATE111093T1 (de) Verfahren zur herstellung von enantiomeren von 3- aminchromanderivaten.
DE69426790T2 (de) Verfahren zur Fraktionierung von deacylierten Glycerophospholipiden
DE59303525D1 (de) Verfahren zur Herstellung von N-(2-Hydroxypropyl)-2,6-dimethylmorpholin
DE69331305D1 (de) Zwischenprodukte und Verfahren zur Herstellung von 5,6-Dihydropyrrolo[2,3-d]pyrimidinen
ES2068040T3 (es) Sales de 3-(cis-2,6-dimetilpiperidino)-sidnonimina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0874847

Country of ref document: EP